Toxic epidermal necrolysis and stevens-johnson syndrome caused by topical ophthalmic use of dorzolamide

Korean Journal of Dermatology

Volumn 47, Issue 3, 2009, Pages 317-321

  Kim, Jae Wang ^b   Shin, Sang Yop ^a  

^a Jeju National University School of Medicine   (South Korea)

^b NONE

Author keywords

Dorzolamide; Stevens johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

EID: 68949211809     PISSN: 04944739     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007:56:181-200
2. 2. Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol 1997;115:550-553 (Pubitemid 27172716)
3. 3. Sung KH, Jeong Y, Choi HU, Lee SK. Two cases of HLA-B59 ( + ) Stevens-Johnson syndrome (SJS)-Toxic epidermal necrolysis (TEN) associated with methazolamide treatment. Korean J Dermatol 2005:43:561-563 4. Ha JH, Song JY, Kim HO, Kim JW. A case of StevensJohnson syndrome caused by acetazolamide. Korean J Dermatol 2003;41:248-250 (Pubitemid 40839653)
4. Ahn EY, Lee JB, Lee SC, Won YH. Four cases of Stevens-Johnson syndrome associated with methazolamide treatment. Korean J Dermatol 2000;38:798-801
5. 6. Herkel U, Pfeiffer N. Update on topical carbonic anhydrase inhibitors. Curr Opin Ophthalmol 2001;12:88-93 (Pubitemid 32232078)
6. Balfour JA, Wilde MI. Dorzolamide: a review of its pharmacologic and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997; 10:384-403
7. 8. Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des 2008:14:649-654 (Pubitemid 351736444)
8. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res 2000;19:87-112
9. Cvetkovic RS, Perry CM. Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 2003:20:919-947
10. 11. Florez A, Roson E, Conde A, Gonzalez B, Garcia-Doval I, Torre C, et al. Toxic epidermal necrolysis secondary to timolol, dorzolamide, and lataprost eyedrops. J Am Acad Dermatol 2005;53:909-911 (Pubitemid 41501400)
11. 12. Munshi V, Ahluwalia H. Erythema multiforme after use of topical dorzolamide. J Ocul Pharmacol Ther 2008;24:91-93 (Pubitemid 351156634)
12. Kim DM, Ahn BH, Park KH, Kee CW. A six-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate hypotensive efficacy and safety of 2% dorzolamide vs placebo ophthalmic solution. J Korean Ophthalmol See 1999;40:2575-2582
13. Lee JJ, Chung J, Baek NH. A clinical study of topical 2% dorzolamide (Trusopt) as adjunctive therapy. J Korean Ophthalmol Soc 1997;38:443-449
14. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of StevensJohnson syndrome or toxic epidermal necrolysis. N Eng J Med 1995;333:1600-1608
15. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, StevensJohnson syndrome, and toxic epidermal necrolysis. Results of an international prospective study. Arch Dermatol 2002;138:1019-1024
16. Ueta M, Tokunaga K, Sotozono C, Inatomi T, Yabe T, Matsushita M, et al. HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vis 2008;14:550-555